

今回の記者発表にかかわる協議会関係者による発表論文

東京大学医学部 蔵野信講師、矢富裕教授ら

(1) Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.

Yokoyama R, Kurano M, Morita Y, Shimura T, Nakano Y, Qian C, Xia F, He F, Kishi Y, Okada J, Yoshikawa N, Nagura Y, Okazaki H, Moriya K, Seto Y, Kodama T, Yatomi Y. PLoS One. 2021 Mar 4;16(3):e0247711.

(2) Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.

Nakano Y, Kurano M, Morita Y, Shimura T, Yokoyama R, Qian C, Xia F, He F, Kishi Y, Okada J, Yoshikawa N, Nagura Y, Okazaki H, Moriya K, Seto Y, Kodama T, Yatomi Y. Sci Rep. 2021 Feb 2;11(1):2776.

東京都医学総合研究所 小原道法研究員ら

(3) Serologic survey of IgG against SARS-CoV-2 among hospital visitors without a history of SARS-CoV-2 infection in Tokyo, 2020-2021.

Sanada T, Honda T, Yasui F, Yamaji K, Munakata T, Yamamoto N, Kurano M, Matsumoto Y, Kohno R, Toyama S, Kishi Y, Horibe T, Kaneko Y, Kakegawa M, Fukui K, Kawamura T, Daming W, Qian C, Xia F, He F, Yamasaki S, Nishida A, Harada T, Higa M, Tokunaga Y, Takagi A, Itokawa M, Kodama T, Kohara M. J Epidemiol. 2021 Nov 13.

福島県立医大 坪倉正治教授 小橋友理江先生ら

(4) Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.

Kobashi Y, Nishikawa Y, Kawamura T, Kodama T, Shimazu Y, Obara D, Zhao T, Tsubokura M.

Int Immunopharmacol. 2021 Sep;98:107884.

(5) The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers.

Kobashi Y, Shimazu Y, Nishikawa Y, Kawamura T, Kodama T, Obara D, Tsubokura M. Int Immunopharmacol. 2021 Mar;92:107360.